CPA
VTGN icon

Cowen Prime Advisors’s VistaGen Therapeutics VTGN Stock Holding History

Cowen Prime Advisors’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-80
Closed -$4K – 189
2018
Q4 		$4K Buy
+80
New +$4.36K ﹤0.01% 165
2018
Q3 		– Sell
-113
Closed -$5K – 210
2018
Q2 		$5K Buy
+113
New +$3.93K ﹤0.01% 190

Other funds holding VTGN

SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cowen Prime Advisors's VTGN Position: Q1 2019 in Review

Cowen Prime Advisors sold out of VistaGen Therapeutics (VTGN) in Q1 2019, closing a stake of 80 shares — an estimated $4K sold.

Cowen Prime Advisors first reported a position in VTGN in Q2 2018 and held it in 2 quarters. The position peaked at $5K in Q2 2018. 25 funds tracked by Wall St. Rank hold VTGN as of Q1 2019.

  • Cowen Prime Advisors reported no remaining VistaGen Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Cowen Prime Advisors sold 80 VistaGen Therapeutics shares in Q1 2019, an estimated $4K.
  • Cowen Prime Advisors first reported a position in VistaGen Therapeutics in Q2 2018 and held it in 2 quarters.
  • Cowen Prime Advisors's VistaGen Therapeutics position peaked at $5K in Q2 2018.
  • 25 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2019.

Based on Cowen Prime Advisors's 13F filing for Q1 2019, filed 29 Apr 2019.